Mapi - Pharma (Mapi - Pharma) Price-to-Tangible-Book : 0.00 (As of Jun. 08, 2024)

View and export this data going back to . Start your Free Trial

What is Mapi - Pharma Price-to-Tangible-Book?

As of today (2024-06-08), Mapi - Pharma's share price is $0.00. Mapi - Pharma's Tangible Book per Share of Jun. 2015 for the quarter that ended in Jun. 2015 was $1.28. Hence, Mapi - Pharma's Price to Tangible Book Ratio of today is 0.00.

The historical rank and industry rank for Mapi - Pharma's Price-to-Tangible-Book or its related term are showing as below:

MAPI's Price-to-Tangible-Book is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 2.265
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Mapi - Pharma's share price is $0.00. Mapi - Pharma's Book Value per Sharefor the quarter that ended in Jun. 2015 was $1.28. Hence, Mapi - Pharma's P/B Ratio of today is 0.00.

Mapi - Pharma Price-to-Tangible-Book Historical Data

The historical data trend for Mapi - Pharma's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma Price-to-Tangible-Book Chart

Mapi - Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Price-to-Tangible-Book

Mapi - Pharma Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15
Price-to-Tangible-Book	-	-	-	-	-

Competitive Comparison of Mapi - Pharma's Price-to-Tangible-Book

For the Drug Manufacturers - Specialty & Generic subindustry, Mapi - Pharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mapi - Pharma's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mapi - Pharma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Mapi - Pharma's Price-to-Tangible-Book falls into.

Mapi - Pharma Price-to-Tangible-Book Calculation

Mapi - Pharma's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Jun. 2015 )
	=	0.00	/	1.282
	=	0.00

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Mapi - Pharma Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Mapi - Pharma (Mapi - Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.mapi-pharma.com

Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.